These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the Multicenter Onychomycosis Study of Terbinafine. Elewski BE Arch Dermatol; 1997 Oct; 133(10):1317-8. PubMed ID: 9382581 [No Abstract] [Full Text] [Related]
14. Management of onychomycosis in children. Gupta AK; De Rosso JQ Postgrad Med; 1999 Jul; Spec No():31-7. PubMed ID: 10492664 [TBL] [Abstract][Full Text] [Related]
15. Continuous terbinafine versus intermittent itraconazole for toenail onychomycosis. Warrick D; Church L J Fam Pract; 1999 Jul; 48(7):492-3. PubMed ID: 10428238 [No Abstract] [Full Text] [Related]
16. [The modern approach to the treatment for onychomycosis of hands and feet in the outpatient setting]. Gerasimchuk EV; Gerasimov VV; Molchanov BA Voen Med Zh; 2005 Nov; 326(11):44-5. PubMed ID: 16404907 [No Abstract] [Full Text] [Related]
17. The interaction of terbinafine and cyclosporine A in renal transplant patients. Lo AC; Lui SL; Lo WK; Chan DT; Cheng IK Br J Clin Pharmacol; 1997 Mar; 43(3):340-1. PubMed ID: 9088596 [No Abstract] [Full Text] [Related]
18. Onychocryptosis as consequence of effective treatment of dermatophytic onychomycosis. Bonifaz A; Paredes V; Fierro L J Eur Acad Dermatol Venereol; 2007 May; 21(5):699-700. PubMed ID: 17447997 [No Abstract] [Full Text] [Related]